子宫内膜异位症相关生物标志物的研究进展

doi:10.12280/gjfckx.20200561

摘要/Abstract

摘要：

子宫内膜异位症（endometriosis,EMs）是子宫内膜的腺体和间质组织种植于子宫腔外的一种慢性的、激素依赖性疾病,已成为妇科常见的疾病之一。由于该病的发病机制尚不清楚,EMs的临床诊断和治疗仍缺乏足够敏感和特异的体征、症状以及可用于血液检测的生物标志物,因此寻找更有效的非侵入性诊断方法对提高EMs患者的临床疗效提供了新思路。EMs慢性炎症过程中涉及的激素、细胞因子、肿瘤相关的糖类抗原、表观调控相关的分子标志物、循环子宫内膜细胞等已在EMs的发病机制中得到了广泛的研究,寻找高敏感度和特异度的EMs生物标志物作为EMs诊断和监测的辅助手段具有重要的意义。随着分子生物学和生物信息学方法的发展,利用高通量组学技术有望挖掘出与EMs相关的特异分子标志物。

关键词: 子宫内膜异位症, 生物标记, 高通量筛选技术, 诊断

Abstract:

Endometriosis (EMs) is a common gynecologic disease and characterized as a chronic and hormone-dependent disease in which endometrial glands and interstitial tissue are implanted outside the uterine cavity. Despite decades of research, there are no sufficiently sensitive and specific signs and symptoms nor accepted biomarkers for the clinical definitively diagnosis of EMs, which hampers prompt diagnosis and treatment. To identify more effective non-invasive diagnostic biomarkers may provide a new thought for improving the clinical efficacy of EMs patients. Hormones, cytokines, chemokines, tumor-associated carbohydrate antigens, biomarkers related to epigenetic regulation and circulating endometrial cells involved in the chronic inflammation of EMs have been extensively studied in the pathogenesis of EMs, but currently no one can be a specific biomarker for EMs. It is of great significance to find highly sensitive and specific EMs biomarkers or a group of biomarkers as auxiliary methods for the diagnosis and monitoring of EMs. With the development of molecular biology and bioinformatics methods, screening approach using high-throughput technologies is expected to discover specific molecular markers related to this disease. This article reviews the latest research progress of EMs-related biomarkers.

Key words: Endometriosis, Biomarkers, High-throughput screening, Diagnosis

江妹, 岳文涛. 子宫内膜异位症相关生物标志物的研究进展[J]. 国际妇产科学杂志, 2021, 48(1): 5-9.

JIANG Mei, YUE Wen-tao. Research Progress of Biomarkers Related to Endometriosis[J]. Journal of International Obstetrics and Gynecology, 2021, 48(1): 5-9.

参考文献 30

[1]	Peiris AN, Chaljub E, Medlock D. Endometriosis[J]. JAMA, 2018,320(24):2608. doi: 10.1001/jama.2018.17953. doi: 10.1001/jama.2018.17953 pmid: 30575883
[2]	Laganà AS, Garzon S, Götte M, et al. The Pathogenesis of Endometriosis: Molecular and Cell Biology Insights[J]. Int J Mol Sci, 2019,20(22):5615. doi: 10.3390/ijms20225615. doi: 10.3390/ijms20225615
[3]	Kitawaki J, Ishihara H, Koshiba H, et al. Usefulness and limits of CA-125 in diagnosis of endometriosis without associated ovarian endometriomas[J]. Hum Reprod, 2005,20(7):1999-2003. doi: 10.1093/humrep/deh890. doi: 10.1093/humrep/deh890 pmid: 15890727
[4]	Hirsch M, Duffy J, Davis CJ, et al. Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta-analysis[J]. BJOG, 2016,123(11):1761-1768. doi: 10.1111/1471-0528.14055. doi: 10.1111/1471-0528.14055 pmid: 27173590
[5]	Nisenblat V, Bossuyt PM, Shaikh R, et al. Blood biomarkers for the non-invasive diagnosis of endometriosis[J]. Cochrane Database Syst Rev, 2016(5):CD012179. doi: 10.1002/14651858.CD012179. doi: 10.1002/14651858.CD008493.pub4 pmid: 27219528
[6]	Asghari S, Valizadeh A, Aghebati-Maleki L, et al. Endometriosis: Perspective, lights, and shadows of etiology[J]. Biomed Pharmacother, 2018,106:163-174. doi: 10.1016/j.biopha.2018.06.109 pmid: 29958140
[7]	Knific T, Fishman D, Vogler A, et al. Multiplex analysis of 40 cytokines do not allow separation between endometriosis patients and controls[J]. Sci Rep, 2019,9(1):16738. doi: 10.1038/s41598-019-52899-8. doi: 10.1038/s41598-019-52899-8 pmid: 31723213
[8]	Nielsen NM, Jørgensen KT, Pedersen BV, et al. The co-occurrence of endometriosis with multiple sclerosis, systemic lupus erythematosus and Sjogren syndrome[J]. Hum Reprod, 2011,26(6):1555-1559. doi: 10.1093/humrep/der105. doi: 10.1093/humrep/der105
[9]	Coutinho LM, Ferreira MC, Rocha A, et al. New biomarkers in endometriosis[J]. Adv Clin Chem, 2019,89:59-77. doi: 10.1016/bs.acc.2018.12.002. doi: 10.1016/bs.acc.2018.12.002 pmid: 30797471
[10]	Maia LM, Rocha AL, Del Puerto HL, et al. Plasma urocortin-1 as a preoperative marker of endometriosis in symptomatic women[J]. Gynecol Endocrinol, 2018,34(3):202-205. doi: 10.1080/09513590.2017.1380188. doi: 10.1080/09513590.2017.1380188 pmid: 28925754
[11]	Pergialiotis V, Tagkou NM, Tsimpiktsioglou A, et al. Urocortin Expression in Endometriosis: A Systematic Review[J]. Int J Fertil Steril, 2019,13(1):1-5. doi: 10.22074/ijfs.2019.5488. doi: 10.22074/ijfs.2019.5488 pmid: 30644237
[12]	Hsiao KY, Wu MH, Tsai SJ. Epigenetic regulation of the pathological process in endometriosis[J]. Reprod Med Biol, 2017,16(4):314-319. doi: 10.1002/rmb2.12047. doi: 10.1002/rmb2.12047 pmid: 29259483
[13]	Koike N, Higashiura Y, Akasaka J, et al. Epigenetic dysregulation of endometriosis susceptibility genes(Review)[J]. Mol Med Rep, 2015,12(2):1611-1616. doi: 10.3892/mmr.2015.3635. doi: 10.3892/mmr.2015.3635 pmid: 25891066
[14]	Bjorkman S, Taylor HS. MicroRNAs in endometriosis: biological function and emerging biomarker candidates?[J]. Biol Reprod, 2019,100(5):1135-1146. doi: 10.1093/biolre/ioz014. doi: 10.1093/biolre/ioz014 pmid: 30721951
[15]	Moga MA, Bălan A, Dimienescu OG, et al. Circulating miRNAs as Biomarkers for Endometriosis and Endometriosis-Related Ovarian Cancer-An Overview[J]. J Clin Med, 2019,8(5):735. doi: 10.3390/jcm8050735. doi: 10.3390/jcm8050735
[16]	Bobek V, Kolostova K, Kucera E. Circulating endometrial cells in peripheral blood[J]. Eur J Obstet Gynecol Reprod Biol, 2014,181:267-274. doi: 10.1016/j.ejogrb.2014.07.037. doi: 10.1016/j.ejogrb.2014.07.037 pmid: 25195200
[17]	Chen Y, Zhu HL, Tang ZW, et al. Evaluation of Circulating Endometrial Cells as a Biomarker for Endometriosis[J]. Chin Med J(Engl), 2017,130(19):2339-2345. doi: 10.4103/0366-6999.215325.
[18]	Pospisilova E, Kiss I, Souckova H, et al. Circulating Endometrial Cells: A New Source of Information on Endometriosis Dynamics[J]. J Clin Med, 2019,8(11):1938. doi: 10.3390/jcm8111938. doi: 10.3390/jcm8111938
[19]	Misra BB, Langefeld CD, Olivier M, et al. Integrated Omics: Tools, Advances, and Future Approaches[J]. J Mol Endocrinol, 2018 Jul 13; JME-18-0055. doi: 10.1530/JME-18-0055. doi: 10.1530/JME-20-0230 pmid: 33112823
[20]	Rahmioglu N, Nyholt DR, Morris AP, et al. Genetic variants underlying risk of endometriosis: insights from meta-analysis of eight genome-wide association and replication datasets[J]. Hum Reprod Update, 2014,20(5):702-716. doi: 10.1093/humupd/dmu015. doi: 10.1093/humupd/dmu015
[21]	Pagliardini L, Gentilini D, Sanchez AM, et al. Replication and meta-analysis of previous genome-wide association studies confirm vezatin as the locus with the strongest evidence for association with endometriosis[J]. Hum Reprod, 2015,30(4):987-993. doi: 10.1093/humrep/dev022. doi: 10.1093/humrep/dev022 pmid: 25678572
[22]	Hudson QJ, Perricos A, Wenzl R, et al. Challenges in uncovering non-invasive biomarkers of endometriosis[J]. Exp Biol Med(Maywood), 2020,245(5):437-447. doi: 10.1177/1535370220903270.
[23]	Suryawanshi S, Vlad AM, Lin HM, et al. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer[J]. Clin Cancer Res, 2013,19(5):1213-1224. doi: 10.1158/1078-0432.CCR-12-2726. doi: 10.1158/1078-0432.CCR-12-2726 pmid: 23362326
[24]	Pateisky P, Pils D, Szabo L, et al. hsa-miRNA-154-5p expression in plasma of endometriosis patients is a potential diagnostic marker for the disease[J]. Reprod Biomed Online, 2018,37(4):449-466. doi: 10.1016/j.rbmo.2018.05.007. doi: 10.1016/j.rbmo.2018.05.007 pmid: 29857988
[25]	Vanhie A, O D, Peterse D, et al. Plasma miRNAs as biomarkers for endometriosis[J]. Hum Reprod, 2019,34(9):1650-1660. doi: 10.1093/humrep/dez116. doi: 10.1093/humrep/dez116 pmid: 31411334
[26]	Wang WT, Sun YM, Huang W, et al. Genome-wide Long Non-coding RNA Analysis Identified Circulating LncRNAs as Novel Non-invasive Diagnostic Biomarkers for Gynecological Disease[J]. Sci Rep, 2016,6:23343. doi: 10.1038/srep23343. doi: 10.1038/srep23343 pmid: 26987697
[27]	Manousopoulou A, Hamdan M, Fotopoulos M, et al. Integrated Eutopic Endometrium and Non-Depleted Serum Quantitative Proteomic Analysis Identifies Candidate Serological Markers of Endometriosis[J]. Proteomics Clin Appl, 2019,13(3):e1800153. doi: 10.1002/prca.201800153. doi: 10.1002/prca.201800153 pmid: 30488576
[28]	Irungu S, Mavrelos D, Worthington J, et al. Discovery of non-invasive biomarkers for the diagnosis of endometriosis[J]. Clin Proteomics, 2019,16:14. doi: 10.1186/s12014-019-9235-3. doi: 10.1186/s12014-019-9235-3 pmid: 30992697
[29]	Vicente-Muñoz S, Morcillo I, Puchades-Carrasco L, et al. Pathophysiologic processes have an impact on the plasma metabolomic signature of endometriosis patients[J]. Fertil Steril, 2016, 106(7):1733-1741.e1. doi: 10.1016/j.fertnstert.2016.09.014. doi: 10.1016/j.fertnstert.2016.09.014 pmid: 27793377
[30]	Braga D, Montani DA, Setti AS, et al. Metabolomic profile as a noninvasive adjunct tool for the diagnosis of Grades III and IV endometriosis-related infertility[J]. Mol Reprod Dev, 2019,86(8):1044-1052. doi: 10.1002/mrd.23221. doi: 10.1002/mrd.23221 pmid: 31215101